FDA explores pilot program to accelerate first-in-human trials
The FDA is working with stakeholders including Amgen and Memorial Sloan Kettering to design a pilot that could shorten the timeline for early-stage drug studies. The initiative aims to make the US more competitive with countries like China and Australia, which currently move faster on such trials. Details of the program are still being finalized.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Amgen, academic centers weigh new FDA pilot to speed early drug trials.” Browse more stories.